Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets
Albrecht Stenzinger1, Daniel Kazdal2, Solange Peters3
1Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg partner site, Heidelberg, Germany; German Center for Lung Research (DZL), Heidelberg partner site, Heidelberg, Germany.
Cell
|January 28, 2021
Summary
Researchers identified genomic biomarkers to predict responses to cancer immunotherapy. This big-data analysis across diverse cancer types offers new tools for precision medicine and treatment selection.
Area of Science:
- Oncology
- Immunology
- Genomics
Background:
- Immune checkpoint blockers have revolutionized cancer therapy.
- Identifying predictive biomarkers for immunotherapy response is crucial for treatment optimization.
- Understanding tumor immunity complexity is key to developing effective cancer treatments.
Purpose of the Study:
- To identify genomic biomarkers that predict immunotherapy response.
- To leverage big-data analysis for discovering cross-cancer predictive markers.
- To advance precision medicine in oncology.
Main Methods:
- Conducted a comprehensive big-data analysis.
- Utilized the largest series of homogenized molecular and clinical datasets.
- Employed advanced analytical approaches to identify genomic features.
Main Results:
- Identified a set of genomic biomarkers.
- These biomarkers predict immunotherapy responders.
- The findings are applicable across various cancer types.
Conclusions:
- Genomic biomarkers can effectively predict immunotherapy response.
- Big-data approaches are powerful for biomarker discovery in oncology.
- These findings support the development of personalized cancer therapies.
Related Concept Videos
01:21Factors Affecting Drug Response: Overview
3.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.1K
01:30Quantitative Aspects of Drug-Receptor Interaction
2.2K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
2.2K
01:20Drug Product Performance: In Vitro–In Vivo Correlation
431
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
431
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97